AI-powered drug-maker
Recursion Pharmaceuticals secures USD 121 M to accelerate its clinical programs
Recursion Pharmaceuticals, a
next-gen biopharma company, has raised USD 121 Million in Series C
financing. The Series C round was led by Baillie Gifford's flagship
investment trust, Scottish Mortgage Investment Trust PLC, with participation by
new institutional investors Intermountain Ventures, Regents of the University
of Minnesota, Texas Tech University System, and few additional angel investors.
Combining artificial intelligence with drug discovery, the company plan to use
the proceeds to fuel its drug discovery platform along with discovering and
adding new ch...